Pablo González‐Bustos

The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia

Antonio Gallo, Leopoldo Pérez de Isla, Sybil Charrière et al. · JACC. Cardiovascular imaging · 2021 · 83 citations

Medicine, Cardiology, Health Sciences +17

Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study

Rodrigo Alonso, Raquel Arroyo-Olivares, Ovidio Muñiz-Grijalvo et al. · European Journal of Preventive Cardiology · 2022 · 28 citations · Full text

Medicine, Cardiology, Pharmacology +17

Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience

Rodrigo Alonso, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz et al. · Journal of clinical lipidology · 2021 · 18 citations

Medicine, Cardiology, Pharmacology +15

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

Marina Blanco‐Ruiz, Laura Amaya‐Pascasio, Reyes de Torres Chacón et al. · Atherosclerosis Plus · 2021 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study

Leopoldo Pérez de Isla, Antonio J. Vallejo‐Vaz, Gerald F. Watts et al. · The Lancet Diabetes & Endocrinology · 2024 · 16 citations

Medicine, Cardiology, Genetics +17